New drug combo for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer that has spread beyond one lung.
- You must not have received any prior chemotherapy or radiation for this lung cancer.
- You must be at least 18 years old, with a life expectancy of at least 3 months.
- You should be able to do light activities (like walking or light housework) on your own.
- You must be willing to provide a tissue sample from a previous biopsy or a new one.
- You cannot have active autoimmune disease, brain metastases, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
This trial tests a new drug combination (BL-M14D1 and Atezolizumab) for people with extensive-stage small cell lung cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow the growth of the cancer.
This trial is testing a new combination of two drugs (QLC5508 and QL2107) compared to the standard treatment (tislelizumab plus chemotherapy) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the new combination works better at controlling the cancer.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (BMS-986489 with chemotherapy) against the current standard treatment (atezolizumab with chemotherapy) for people who have just been diagnosed with extensive-stage small cell lung cancer. It aims to see which approach works better and is safer.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.